Importance of Early Blood Sampling on Vecuronium Pharmacokinetic and Pharmacodynamic Parameters

SummaryThe effect of early blood sampling on the description of the vecuronium pharmacokinetic-pharmacodynamic relationship was studied following a bolus injection. Sample collection every 10 sec during the first 2 min showed a high concentration peak at 30 to 40 sec, accounting for an important proportion of the total area under the plasma concentration-time curve (AUC). Neglecting it, using only blood samples drawn at 1 and 2 min (limited sampling), led to a significant overestimation of noncompartmentally derived values of mean residence time, clearance, volume of distribution at steady-state and rate of transfer of vecuronium into the effect compartment. Compartmental pharmacokinetics could not be applied to concentration-time curves constructed with early samples, but limited sampling data were fitted to a 2-compartment model. Derived compartmental pharmacokinetic and pharmacokinetic-pharmacodynamic parameters were similar to those obtained noncompartmentally with complete sampling every 10 sec, because back-extrapolation to time zero contributed to the increase in the AUC. However, compartmental analysis does not provide an accurate description of concentration changes following injection.

[1]  Pharmacokinetics and pharmacodynamics of atracurium obtained with arterial and venous blood samples , 1991, Clinical pharmacology and therapeutics.

[2]  R. Miller,et al.  Pharmacokinetics, neuromuscular effects, and biodisposition of 3-desacetylvecuronium (Org 7268) in cats. , 1991, Anesthesiology.

[3]  J. B. Cohen,et al.  Kinetics of binding of [3H]acetylcholine to Torpedo postsynaptic membranes: association and dissociation rate constants by rapid mixing and ultrafiltration. , 1980, Biochemistry.

[4]  G. Schwarz.  Estimating the Dimension of a Model , 1978 .

[5]  L. Sheiner,et al.  Understanding the Dose-Effect Relationship , 1981, Clinical pharmacokinetics.

[6]  D. S. Savage,et al.  The Emergence of ORG NC 45, 1- [(2β,3α, 5α,16β, 17β)-3, 17-BIS(Acetyloxy)-2-(1-Piperidinyl)-Androstan-16-YL]-1-Methylpiperidinium Bromide, from the Pancuronium Series , 1980 .

[7]  H. H. Ali,et al.  Monitoring of Neuromuscular Function , 1976, Anesthesiology.

[8]  F. Donati,et al.  High-performance liquid chromatography-electrochemical detection of vecuronium and its metabolites in human plasma. , 1992, Journal of chromatography.

[9]  C. Meistelman,et al.  Disposition and Urinary Excretion of Vecuronium Bromide in Anesthetized Patients with Normal Renal Function or Renal Failure , 1986, Anesthesia and analgesia.

[10]  L B Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models , 1986, Clinical pharmacology and therapeutics.

[11]  D. O'Hara,et al.  Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia , 1987, Clinical pharmacology and therapeutics.

[12]  W. L. Chiou,et al.  The Phenomenon and Rationale of Marked Dependence of Drug Concentration on Blood Sampling Site , 1989, Clinical pharmacokinetics.

[13]  R. Miller,et al.  Pancuronium and Vecuronium Pharmacokinetics and Pharmacodynamics in Younger and Elderly Adults , 1987, Anesthesiology.

[14]  John C. Cannon,et al.  Vecuronium in Alcoholic Liver Disease: A Pharmacokinetic and Pharmacodynamic Analysis , 1988, Anesthesiology.

[15]  C. Lien,et al.  Distribution, Elimination, and Action of Vecuronium in the Elderly , 1991, Anesthesia and analgesia.

[16]  L B Sheiner,et al.  Simultaneous Modeling of Pharmacokinetics and Pharmacodynamics with a Nonparametric Pharmacodynamic Model , 1984, Clinical pharmacology and therapeutics.

[17]  P. Duvaldestin,et al.  PHARMACOKINETICS AND PHARMACODYNAMICS OF VERCURONUIUM IN PATIENTS WITH CHOLESTASIS , 1986 .

[18]  F. Donati,et al.  Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. , 1991, British journal of anaesthesia.

[19]  P. Duvaldestin,et al.  Pharmacokinetics and Pharmacodynamics of Vecuronium (ORG NC 45) in Patients with Cirrhosis , 1985, Anesthesiology.

[20]  H. Boxenbaum,et al.  Pharmacokinetics: philosophy of modeling. , 1992, Drug metabolism reviews.

[21]  Lewis B. Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine , 1979 .

[22]  J. Swarbrick.  Drugs and the pharmaceutical sciences , 1975 .

[23]  R. Miller,et al.  Pharmacokinetics of Org NC45 (norcuron) in patients with and without renal failure. , 1981, British journal of anaesthesia.

[24]  A. Bencini,et al.  Pharmacokinetics and pharmacodynamics of Org NC 45 in man. , 1980, British journal of anaesthesia.

[25]  A. Scaf,et al.  Comparative Pharmacokinetics and Dynamics of Vecuronium and Pancuronium in Anesthetized Patients , 1986, Anesthesia and analgesia.

[26]  J. Stovner,et al.  Artery-to-muscle onset time for neuromuscular blocking drugs. , 1980, British journal of anaesthesia.

[27]  C. Meistelman,et al.  Pharmacology of vecuronium in patients with end-stage renal failure. , 1986, European Journal of Anaesthesiology.

[28]  Ronald D. Miller,et al.  The Pharmacodynamics and Pharmacokinetics of Vecuronium in Patients Anesthetized with Isoflurane with Normal Renal Function or with Renal Failure , 1988, Anesthesiology.

[29]  R. Miller,et al.  Pharmacokinetics and Pharmacodynamics of Vecuronium (ORG NC45) and Pancuronium in Anesthetized Humans , 1983, Anesthesiology.

[30]  B Sakmann,et al.  Fast events in single‐channel currents activated by acetylcholine and its analogues at the frog muscle end‐plate. , 1985, The Journal of physiology.

[31]  J. Wierda,et al.  Dose‐Response Relation, Neuromuscular Blocking Action, Intubation Conditions, and Cardiovascular Effects of Org 9273, a New Neuromuscular Blocking Agent , 1991, Anesthesia and analgesia.